Introducing
ATRISORB® FreeFlow GTR Barrier:
- The first and only barrier customized directly at the surgical
site
- Eliminates cutting, trimming or handling of preformed barriers
- Reduces surgical time because barrier is formed directly at
the surgical site
- Unique flowable polymer readily adapts to root morphology
Bioadhesive:
- No stabilizing sutures required
- Adheres directly to tooth and surrounding bone
Bioabsorbable:
- Eliminates the need for second surgery
- Maintains structrual integrity for approximately 6 months
- Complete bioabsorption within 9-12 months
Economical:
- Each sterile, single-patient use syringe treats multiple defects
in one patient visit
- Eliminates costly inventory of barrier shapes and sizes
Combined
surgical approach in intrabony lesions:
- Mean gain of 50% in CAL from baseline
- Mean PD at 6 months reduced on average by >60% to 5 mm
or less
Atrisorb-D
FreeFlow GTR Barrier:
- The only Barrier that contains
an antibiotic-doxycycline 4%
- Provides controlled release of doxycycline for a period
of 7 days
- Proven to prevent bacterial colonization of the barrier
Patients
who are allergic to NMP or PLA should not be treated with
ATRISORB-D FreeFlow™ Barrier. ATRISORB-D FreeFlow Barrier
is contraindicated in those situations where general periodontal
surgery should not be performed. ATRISORB-D FreeFlow contains
doxycycline (4%). The use of tetracycline drugs during tooth
development (last half of pregnancy) may cause permanent discoloration
of the teeth. Tetracycline drugs should not be used in infants,
children up to the age of 8 years or pregnant or nursing women
unless other treatment is not likely to be effective or if
alternative therapy is contraindicated. Tetracyclines as a
class are associated with photosensitivity. Treatment should
be discontinued at the first sign of cutaneous erythema. Please
see Full Prescribing Information for adverse reactions, warnings,
and contraindications.
ATRISORB®
is a registered trademark of TOLMAR, Inc.
